Factor VIII desensitising patch - DBV Technologies/INSERM
Latest Information Update: 19 Nov 2021
At a glance
- Originator DBV Technologies; INSERM
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Allergy in France (Intradermal, Patch)
- 04 Mar 2016 Pharmacodynamics data from a preclinical trial in Hypersensitivity to Factor VIII in Haemophilia A presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
- 22 Oct 2013 Preclinical trials in Hypersensitivity to Factor VIII in Haemophilia A in France (Topical)